{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-26-000002","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.227603+00:00","generated_at":"2026-05-16T03:21:28.385085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Royalty Pharma Reports Q4 and Full Year 2025 Results; Portfolio Receipts Up 18% and 16% Respectively","bullets":["Portfolio Receipts reached $874M in Q4 2025 (up 18%) and $3,254M for FY 2025 (up 16%).","Net cash from operating activities was $827M in Q4 and $2,490M for FY 2025.","Deployed $2.6B in capital on royalty transactions in 2025, including nine new therapies.","Repurchased 37M shares for $1.2B and increased quarterly dividend by 7% to $0.235.","Provided FY 2026 guidance: Portfolio Receipts expected between $3,275M and $3,425M."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-26-000002","json":"https://secwatch.observer/filing/0001802768-26-000002.json","markdown":"https://secwatch.observer/filing/0001802768-26-000002.md","text":"https://secwatch.observer/filing/0001802768-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/0001802768-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/rprx-20260211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T03:21:28.385085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}